Cohealyx I Hits Primary Endpoint: Grafts Ready in Median 11 Days
RCEL has more than doubled off its 52-week low of $3.22.
Summary
AVITA's Cohealyx I study in full-thickness wounds met its primary endpoint, with median graft readiness at 11 days and 72% of grafts ready within two weeks. No Cohealyx-related adverse events were reported across the 26-week follow-up after grafting. The readout lands two weeks after Q3 results showed revenue up 53% to $26.1M at an 84.0% gross margin and guidance raised to $92M-$94M, so this is clinical validation for the product line rather than a financial update. Cohealyx is a spray-on skin product for full-thickness wounds, and clean six-month safety plus fast readiness is the kind of data that supports adoption and reimbursement conversations. No specific upcoming regulatory or commercial milestone was disclosed in the release.
At the time of this announcement, RCEL was trading at $16.20 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $491.1M. The 52-week trading range was $3.22 to $18.43. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: Reuters.